article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis Ā® in mainland China (the “License Agreement”). million and US$1.8

article thumbnail

CHMP recommends EU approvalĀ 

The Pharma Data

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel

The Pharma Data

These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP). AR-101 (HAP).

article thumbnail

Biopharma Leaders Unite To Stand With Science

The Pharma Data

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the worldā€™s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

article thumbnail

Biopharma Leaders Unite To Stand With Science

The Pharma Data

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the worldā€™s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

article thumbnail

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

Advarra

This will aid clinical development and preparation for investigational new drug (IND) and biologics license application (BLA) submissions. The project should also help clinical research sponsors take advantage of various FDA pathways for accelerated review and approval.